H1 (Interim)
ABVX — H1 2026 Financial Report Analysis
Abivax’s H1 2026 net loss widened to €165.9M, driven mostly by a non-cash €43.2M royalty-buyback charge and €39.4M of share-based pay, while ~€1.17bn of pro forma cash funds it into Q4 2029 ahead of a Q4 2026 US filing for obefazimod in ulcerative colitis.